Phosphorylation of the Proapoptotic BH3-Only Protein Bid Primes Mitochondria for Apoptosis during Mitotic Arrest

Cell Reports

Volumn 7, Issue 3, 2014, Pages 661-671

  Wang, Pengbo ^a   Lindsay, Jennefer ^a   Owens, Thomas W ^a   Mularczyk, Ewa J ^a   Warwood, Stacey ^a   Foster, Fiona ^a   Streuli, Charles H ^a   Brennan, Keith ^a   Gilmore, Andrew P ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BH3 PROTEIN; CASPASE 3; CYTOCHROME C; PROTEIN BCL 2; SERINE; SERINE 66; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; PACLITAXEL; PHOSPHOPEPTIDE; PROTEIN BID; SMALL INTERFERING RNA;

ANAPHASE; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; MASS SPECTROMETRY; METAPHASE; MICROTUBULE; MITOCHONDRION; MITOSIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; AMINO ACID SEQUENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CYCLE CHECKPOINT; CELL LINE; CHEMISTRY; DRUG EFFECTS; HEK293 CELL LINE; HUMAN; METABOLISM; MITOSIS; MOLECULAR GENETICS; PHOSPHORYLATION; ANIMAL CELL; EMBRYO; HUMAN CELL; PROTEIN EXPRESSION;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; CELL CYCLE CHECKPOINTS; CELL LINE; HEK293 CELLS; HUMANS; MICE; MITOCHONDRIA; MITOSIS; MOLECULAR SEQUENCE DATA; PACLITAXEL; PHOSPHOPEPTIDES; PHOSPHORYLATION; RNA, SMALL INTERFERING;

METAZOA;

EID: 84899920659     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2014.03.050     Document Type: Article

References (29)

1. Biswas S., Shi Q., Wernick A., Aiello A., Zinkel S.S. The loss of the BH3-only Bcl-2 family member Bid delays T-cell leukemogenesis in Atm-/- mice. Cell Death Differ. 2013, 20:869-877.
2. Brito D.A., Rieder C.L. Mitotic checkpoint slippage in humans occurs via cyclin B destruction in the presence of an active checkpoint. Curr. Biol. 2006, 16:1194-1200.
3. Certo M., Del Gaizo Moore V., Nishino M., Wei G., Korsmeyer S., Armstrong S.A., Letai A. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 2006, 9:351-365.
4. Degli Esposti M., Ferry G., Masdehors P., Boutin J.A., Hickman J.A., Dive C. Post-translational modification of Bid has differential effects on its susceptibility to cleavage by caspase 8 or caspase 3. J. Biol. Chem. 2003, 278:15749-15757.
5. Del Gaizo Moore V., Letai A. BH3 profiling-measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions. Cancer Lett. 2013, 332:202-205.
6. Deng J., Carlson N., Takeyama K., Dal Cin P., Shipp M., Letai A. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell 2007, 12:171-185.
7. Desagher S., Osen-Sand A., Montessuit S., Magnenat E., Vilbois F., Hochmann A., Journot L., Antonsson B., Martinou J.C. Phosphorylation of bid by casein kinases I and II regulates its cleavage by caspase 8. Mol. Cell 2001, 8:601-611.
8. Gascoigne K.E., Taylor S.S. Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell 2008, 14:111-122.
9. Gilmore A.P., Valentijn A.J., Wang P., Ranger A.M., Bundred N., O'Hare M.J., Wakeling A., Korsmeyer S.J., Streuli C.H. Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor. J. Biol. Chem. 2002, 277:27643-27650.
10. Gross A., Yin X.M., Wang K., Wei M.C., Jockel J., Milliman C., Erdjument-Bromage H., Tempst P., Korsmeyer S.J. Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death. J. Biol. Chem. 1999, 274:1156-1163.
11. Harley M.E., Allan L.A., Sanderson H.S., Clarke P.R. Phosphorylation of Mcl-1 by CDK1-cyclin B1 initiates its Cdc20-dependent destruction during mitotic arrest. EMBO J. 2010, 29:2407-2420.
12. Huang H.-C., Shi J., Orth J.D., Mitchison T.J. Evidence that mitotic exit is a better cancer therapeutic target than spindle assembly. Cancer Cell 2009, 16:347-358.
13. Kamer I., Sarig R., Zaltsman Y., Niv H., Oberkovitz G., Regev L., Haimovich G., Lerenthal Y., Marcellus R.C., Gross A. Proapoptotic BID is an ATM effector in the DNA-damage response. Cell 2005, 122:593-603.
14. Korsmeyer S.J., Wei M.C., Saito M., Weiler S., Oh K.J., Schlesinger P.H. Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. Cell Death Differ. 2000, 7:1166-1173.
15. Llambi F., Moldoveanu T., Tait S.W., Bouchier-Hayes L., Temirov J., McCormick L.L., Dillon C.P., Green D.R. A unified model of mammalian BCL-2 protein family interactions at the mitochondria. Mol. Cell 2011, 44:517-531.
16. Maryanovich M., Oberkovitz G., Niv H., Vorobiyov L., Zaltsman Y., Brenner O., Lapidot T., Jung S., Gross A. The ATM-BID pathway regulates quiescence and survival of haematopoietic stem cells. Nat. Cell Biol. 2012, 14:535-541.
17. Musacchio A., Salmon E.D. The spindle-assembly checkpoint in space and time. Nat. Rev. Mol. Cell Biol. 2007, 8:379-393.
18. Nakano K., Vousden K.H. PUMA, a novel proapoptotic gene, is induced by p53. Mol. Cell 2001, 7:683-694.
19. Rieder C.L., Maiato H. Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint. Dev. Cell 2004, 7:637-651.
20. Sarig R., Zaltsman Y., Marcellus R.C., Flavell R., Mak T.W., Gross A. BID-D59A is a potent inducer of apoptosis in primary embryonic fibroblasts. J. Biol. Chem. 2003, 278:10707-10715.
21. Schellenberg B., Wang P., Keeble J.A., Rodriguez-Enriquez R., Walker S., Owens T.W., Foster F., Tanianis-Hughes J., Brennan K., Streuli C.H., Gilmore A.P. Bax exists in a dynamic equilibrium between the cytosol and mitochondria to control apoptotic priming. Mol. Cell 2013, 49:959-971.
22. Shi J., Zhou Y., Huang H.-C., Mitchison T.J. Navitoclax (ABT-263) accelerates apoptosis during drug-induced mitotic arrest by antagonizing Bcl-xL. Cancer Res. 2011, 71:4518-4526.
23. Sudo T., Nitta M., Saya H., Ueno N.T. Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint. Cancer Res. 2004, 64:2502-2508.
24. Topham C.H., Taylor S.S. Mitosis and apoptosis: how is the balance set?. Curr. Opin. Cell Biol. 2013, 25:780-785.
25. Valentijn A.J., Gilmore A.P. Translocation of full-length Bid to mitochondria during anoikis. J. Biol. Chem. 2004, 279:32848-32857.
26. Wertz I.E., Kusam S., Lam C., Okamoto T., Sandoval W., Anderson D.J., Helgason E., Ernst J.A., Eby M., Liu J., et al. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 2011, 471:110-114.
27. Youle R.J., Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol. 2008, 9:47-59.
28. Zinkel S.S., Ong C.C., Ferguson D.O., Iwasaki H., Akashi K., Bronson R.T., Kutok J.L., Alt F.W., Korsmeyer S.J. Proapoptotic BID is required for myeloid homeostasis and tumor suppression. Genes Dev. 2003, 17:229-239.
29. Zinkel S.S., Hurov K.E., Ong C., Abtahi F.M., Gross A., Korsmeyer S.J. A role for proapoptotic BID in the DNA-damage response. Cell 2005, 122:579-591.